IGF1R and Ewing sarcoma: Eighteen biomarkers in 14 patients indicated at least one to three approved drugs in a given patient: trametinib (ABL1.pK266R; n = 1) plus docetaxel, imatinib (germline KIT.pM541L), lapatinib, cetuximab, IGF‐1R antibody plus temsirolimus (mTOR inhibitor) as a result of the PTPRD.pR995C, Ewing sarcoma, or an AKT‐inhibitor (MK2206) (KRAS.pG12D; n = 13), as well as epirubicin (TP53.pR248Q), paclitaxel (TP53.pR282W) or cisplatin (germline: GSTP1.pI105V).